Investor News / RNS

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, announces that following the receipt of a notice of exercise of employee options, 90,000 ordinary shares of 0.4p each in the Company (“Ordinary Shares”) (the “Options Shares”) will be issued to an employee at an exercise price of 3.16p per option. Application will be made...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Numab Therapeutics (“Numab”). Building on the relationship that was first announced in May this year, a second contract has now been signed relating to a further Numab programme.  The...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has signed new agreements with existing client, Merck KGaA (“Merck”), with an aggregate value of £300,000. These projects are expected to be completed over the course of the next six months and will span a range of...

Read More

Physiomics plc (AIM: PYC), an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's Annual General Meeting, held earlier today at the Company’s offices in Oxford, were duly passed.   Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980 Strand Hanson Ltd (NOMAD) James Dance & James Bellman +44 (0)20...

Read More

Physiomics and Bicycle Therapeutics to present on preclinical modelling of an immune therapy at SITC 2021 Annual Meeting Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is presenting a poster at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place at the Walter...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has today published on its website its Annual Report and Accounts for the financial year ended 30 June 2021, together with its Notice of Annual General Meeting (“AGM”).  Shareholders will be sent either printed copies of these...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts by existing client Merck KGaA (“Merck”) that it expects to be completed by the end of this calendar year.  These projects involve simulations of clinical efficacy of drug products in Merck’s DNA...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions today made a presentation regarding its final results for the year ended 30 June 2021, using the Investor Meet Company platform.  The slide deck used in the presentation will be posted on the Company’s website at https://www.physiomics.co.uk/resources/ and a recording of the presentation, together...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions is pleased to announce its PARTNER study has recruited its first patient.  The study, which received formal Health Research Authority (HRA) ethics approval in December 2020 and started recruiting just this month, has been commissioned to gather data for the further development of Physiomics’...

Read More